Form 8-K - Current report:
SEC Accession No. 0001641172-25-017653
Filing Date
2025-07-03
Accepted
2025-07-02 20:38:20
Documents
22
Period of Report
2025-07-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 59825
2 EX-4.1 ex4-1.htm EX-4.1 102525
3 EX-4.2 ex4-2.htm EX-4.2 134962
4 EX-4.3 ex4-3.htm EX-4.3 140538
5 EX-10.1 ex10-1.htm EX-10.1 427228
6 EX-10.2 ex10-2.htm EX-10.2 171760
7 EX-99.1 ex99-1.htm EX-99.1 12995
8 EX-99.2 ex99-2.htm EX-99.2 12616
9 GRAPHIC ex10-2_01.jpg GRAPHIC 7355
10 GRAPHIC ex10-2_02.jpg GRAPHIC 15184
  Complete submission text file 0001641172-25-017653.txt   1519749

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE lixt-20250702.xsd EX-101.SCH 3784
12 XBRL DEFINITION FILE lixt-20250702_def.xml EX-101.DEF 26650
13 XBRL LABEL FILE lixt-20250702_lab.xml EX-101.LAB 36768
14 XBRL PRESENTATION FILE lixt-20250702_pre.xml EX-101.PRE 25274
24 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5794
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 251103495
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)